Clinical Insights and Reflections on MacTel Type 2 Management

A panelist discusses how key takeaways from multiple macular telangiectasia (MacTel) cases reveal the importance of timing, patient selection, and communication in NT-501 use. They concluded that both eyes may eventually benefit from treatment, though sequencing should prioritize vision preservation. In severe disease, intervention remains a debated but potentially valuable option, emphasizing a case-by-case approach. Participants highlighted that even patients with normal visual acuity may experience functional impairment warranting therapy consideration. Thorough counseling regarding adverse effects—such as delayed dark adaptation—was considered essential for setting realistic expectations. The discussion ended with a consensus that real-world collaboration and experience-sharing enhance confidence in applying this novel therapy, ultimately advancing standards of care in MacTel type 2.